Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel ...
Reports Q4 revenue $$90.55M, consensus $93.85M. Reports LINZESS or Iinaclotide EUTRx prescription demand growth of 11% for full-year 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback